Royalty Report: Drugs, Cancer, Autoimmune – Collection: 29084

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Cancer
  • Autoimmune
  • Pharmaceuticals
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29084

License Grant
The Licensee entered into an Agreement with the Licensor to re-acquire the option rights to CTCE-0214 drug candidate that had previously been granted to the Licensor in April 2003. CTCE-0214 is a hematological support compound. Under this Agreement, the Licensee is obligated to achieve various milestones and committed to make certain milestone payments.
License Property
The drug candidate CTCE-0214 is a synthetic shortened version (analog) of SDF-1.

CTCE-0214 rapidly mobilizes white blood cells (neutrophils), bleeding prevention cells (platelets) and stem cells (primitive blood forming cells) into the blood.  These studies suggest CTCE-0214 has the potential to restore a cancer patients' immune system and blood cells between cycles of chemotherapy. In this clinical scenario, patients may be able to receive aggressive chemotherapy without delay by restoring infection-fighting white blood cells and increasing platelet counts to protect patients from bleeding.

Field of Use
Field of Use relates to the medical industry.

IPSCIO Record ID: 269086

License Grant
This exclusive license agreement with Licensee is to commercialize fostamatinib in all indications, including chronic ITP, AIHA, and IgAN, in Europe and Turkey.  Licensee will receive exclusive rights to fostamatinib in human diseases, including chronic immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and IgA nephropathy (IgAN).
License Property
Fostamatinib refers to fostamatinib disodium hexahydrate which is an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment (product called TAVALISSE®)

The Licensor is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The pioneering research focuses on signaling pathways that are critical to disease mechanisms.

Field of Use
Fostamatinib is a medication for the treatment of chronic immune thrombocytopenia.

Adult chronic immune thrombocytopenic purpura (chronic ITP) is an autoimmune disorder in which patients produce antiplatelet autoantibodies and specialized white blood cells that destroy their blood platelets and, in some cases, damage their megakaryocytes (the cells that produce platelets in the bone marrow), causing a decrease in platelet production. This results in a low blood platelet count (thrombocytopenia) that may produce bruising or excessive bleeding.

IPSCIO Record ID: 337709

License Grant
The parties agree to commercialize fostamatinib in all potential indications, including chronic ITP and AIHA, in Canada and Israel.
License Property
Fostamatinib has the brand name of Tavlesse (Tavalisse). It is a tablet, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment.

ITP means immune thrombocytopenia where the immune system attacks and destroys the body’s own blood platelets, which play an active role in blood clotting and healing. ITP patients can suffer extraordinary bruising, bleeding and fatigue as a result of low platelet counts.

Field of Use
Field of use is for the treatment of thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to other treatments and to reduce the destruction of red blood cells in the AIHA disease.

AIHA means autoimmune hemolytic anemia.  It is is a rare, serious blood disorder where the immune system produces antibodies that result in the destruction of the bodys own red blood cells. Symptoms can include fatigue, shortness of breath, rapid heartbeat, jaundice or enlarged spleen.

IPSCIO Record ID: 319042

License Grant
Licensor and Hong Kong Licensee agreed to collaborate for the development and commercialization of uproleselan and GMI-1687 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China and to advance the preclinical and clinical development of GMI-1687.
License Property
GMI-1687 is a potential life-cycle extension to uproleselan that has been designed as an innovative antagonist of E-selectin that could be suitable for subcutaneous administration.

Uproleselan is a glycomimetic drug candidate and a specific E-selectin inhibitor that is being developed to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, or AML, a life-threatening hematologic cancer, and potentially other hematologic cancers.

E-selectin plays a critical role in binding cancer cells within vascular niches in the bone marrow, which prevents the cells from entering the circulation where they can be more readily killed by chemotherapy.  Glycomimetics are molecules that mimic the structure of carbohydrates involved in biological processes.

Field of Use
The field of use is for the treatment in combination with chemotherapy to treat patients with acute myeloid leukemia (AML) and potentially other hematologic cancers.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.